Dr. Ansbert Gadicke is co-founder and Managing Director of MPM and its venture capital activities, as well as Managing Partner of the Oncology Impact Funds, private/public funds focused on oncology as well as new modalities managed by MPM. He is the driving force at MPM behind building leading biopharmaceutical companies such as BioMarin Pharmaceuticals, Idenix Pharmaceuticals (acquired by Merck & Co.), Mitobridge (acquired by Astellas), and Pharmasset (acquired by Gilead Sciences) and, more recently, Cullinan Oncology (NASDAQ: CGEM), iTeos Therapeutics (NASDAQ: ITOS) and AlloVir (NASDAQ: ALVR). MPM believes that these companies, in which Ansbert was the lead investor and served on the Boards of Directors, are some of the biggest successes in biotech – companies that ultimately result in helping thousands of patients live longer and vastly improved lives. For example, Sovaldi, developed by Pharmasset, was the first cure for Hepatitis C and experienced the most successful product launch in the pharmaceutical industry. Prior to launching MPM’s venture investing activities, Ansbert led MPM’s Advisory and Investment Banking business, and prior to that he was at The Boston Consulting Group in their Boston office.
Ansbert’s commitment to drug discovery and curing disease inspires his work both within and outside of MPM. In recognition of MPM’s novel work to finance and build companies which may have a significant impact on cancer care and cures globally, Ansbert and his co-founder Luke Evnin are recipients of the 2017 Global Oncology Visionary Award. Ansbert is active in guiding MPM portfolio companies and serves as Chairman of the Board at NextPoint Therapeutics, Orna, and TCR2 Therapeutics (NASDAQ: TCRR) and as a Board Director at Cullinan Oncology (NASDAQ: CGEM), ElevateBio and Allovir (NASDAQ: ALVR). He is also a member of the Harvard Medical School Board of Fellows and the Research Advisory Council of Massachusetts General Hospital.
Ansbert received an M.D. from J.W. Goethe University in Frankfurt and held research positions at the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology and the Biochemistry Department at Harvard University. While at the German Cancer Research Center, he focused on HPV16 and 18 in Professor Harald zur Hausen’s group (Nobel Laureate in Physiology or Medicine, 2008). Ansbert has published in leading scientific journals such as Nature and Cell.
What is Ansbert Gadicke's net worth?
The estimated net worth of Ansbert Gadicke is at least $48.56 million as of December 4th, 2025. Dr. Gadicke owns 4,784,111 shares of iTeos Therapeutics stock worth more than $48,558,727 as of December 4th. This net worth estimate does not reflect any other investments that Dr. Gadicke may own. Learn More about Ansbert Gadicke's net worth.
How do I contact Ansbert Gadicke?
Has Ansbert Gadicke been buying or selling shares of iTeos Therapeutics?
Ansbert Gadicke has not been actively trading shares of iTeos Therapeutics over the course of the past ninety days. Most recently, Ansbert Gadicke sold 1,031,931 shares of the business's stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $8.06, for a transaction totalling $8,317,363.86. Following the completion of the sale, the insider now directly owns 3,452,797 shares of the company's stock, valued at $27,829,543.82. Learn More on Ansbert Gadicke's trading history.
Who are iTeos Therapeutics' active insiders?
Are insiders buying or selling shares of iTeos Therapeutics?
During the last year, insiders at the sold shares 11 times. They sold a total of 1,939,307 shares worth more than $16,202,115.73. The most recent insider tranaction occured on June, 10th when CEO Michel Detheux sold 43,883 shares worth more than $439,707.66. Insiders at iTeos Therapeutics own 14.2% of the company.
Learn More about insider trades at iTeos Therapeutics. Information on this page was last updated on 6/10/2025.
